On January 29, 2024 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, reported its participation in the 2024 NeauxCancer Conference organized by the Cancer Advocacy Group of Louisiana (CAGLA), being held February 29 – March 2, 2024 in New Orleans (Press release, Anixa Biosciences, JAN 29, 2024, View Source [SID1234639691]). Anixa Chairman and CEO Dr. Amit Kumar will present and meet one-on-one with investors throughout the day on Friday, March 1st.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kumar’s remarks will feature Anixa’s use of the body’s immune system to take multiple approaches in fighting cancer. The Company’s vaccines focus on immunizing against "retired" proteins found to be expressed in certain forms of cancer, a mechanism that has never before been utilized for cancer vaccine development.

Attendees at the conference will include oncologists and other clinicians interested in learning and discussing the latest practices for treating and taking care of cancer patients. The investment track will enable the medical professionals attending the conference, as well as regional investment professionals, to learn about emerging technologies for cancer treatment and prevention.

Registration and attendance at the conference for investors is complimentary. Investors can register via the link below.

Investment Track Details:

Anixa presentation:

Friday, March 1, 2024, at 11:30 AM CST

Conference registration:

Available on the conference website

1×1 meetings:

Open to investors upon conference registration

Chadwick Landry, President and Executive Director of CAGLA stated, "We are pleased to be adding an investment track to our annual conference. We are also pleased that Anixa will be presenting at this inaugural year of the investment track. We plan to make the investment track a regular event at this well-attended conference to enable regional investors and medical professionals to gain firsthand exposure to some of the most exciting emerging companies developing technologies to address cancer."

The 2024 NeauxCancer Conference has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Ochsner Clinic Foundation and CAGLA. The Ochsner Clinic Foundation is accredited by the ACCME to provide continuing medical education for physicians.